DOI QR코드

DOI QR Code

Clinical Significance of Serum p53 and Epidermal Growth Factor Receptor in Patients with Acute Leukemia

  • Abdel-Aziz, Mohamed Mohamed (Gastroenterology Surgical Center, Faculty of Medicine, Mansoura University)
  • Published : 2013.07.30

Abstract

Background: Pretreatment serum p53 and epidermal growth factor receptor (EGFR) were assessed using enzyme-linked immunosorbent assay (ELISA) in patients with acute leukemia to analysis their roles in characterization of different subtypes of the disease. Materials and Methods: Serum samples from thirty two patients with acute myeloid leukemia (AML) and fourteen patients with acute lymphoid leukemia (ALL) were analysed, along with 24 from healthy individuals used as a control group. Results: The results demonstrated a significant increase of serum p53 and EGFR in patients with AML (p<0.0001) compared to the control group. Also, the results showed a significant increase of both markers in patients with ALL (p<0.05, p<0.0001 respectively). Sensitivities and specificities for these variables were 52% and 100% for p53, and 73.9%, 95.8% for EGFR. Serum p53 and EGFR could successfully differentiate between M4 and other AML subtypes, while these variables failed to discriminate among ALL subtypes. A positive significant correlation was noted between p53 and EGFR. Negative significant correlations were observed between these variables and both of hemoglobin (Hg) content and RBC count. Conclusions: Mutant p53 and EGFR are helpful serological markers for diagnosis of patients with AML or ALL and can aid in characterization of disease. Moreover, these markers may reflect carcinogenesis mechanisms.

Keywords

Acute myeloid leukemia;acute lymphoid leukemia;p53;EGFR;ELISA;ROC

References

  1. Abdel-aziz MM, GadEl-Hak NA, Abbas AT (2005). Clinical significance of serum p53 antigen in patients with hepatocellular carcinoma. Int J Cancer Res, 1, 94-100. https://doi.org/10.3923/ijcr.2005.94.100
  2. Abdel-aziz MM, Lotfy M, El-Kady IM, et al (2009). Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Det Prev, 32, 329-35. https://doi.org/10.1016/j.cdp.2005.10.006
  3. Alachkar H, Xie Z, Marcucci G, et al (2012). Determination of cellular uptake and intracellular levels of Cenersen (Aezea(${\circledR}$), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells. J Pharm Biomed Anal, 71, 228-32. https://doi.org/10.1016/j.jpba.2012.08.011
  4. Anensen N, Hjelle SM, Van Belle W, et al (2012). Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene, 31, 1533-45. https://doi.org/10.1038/onc.2011.348
  5. Attallah AM, Abdel-Aziz MM, El-Sayed AM, et al (2003). Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Det Prev, 27, 127-31. https://doi.org/10.1016/S0361-090X(03)00024-2
  6. Charuruks N, Tangkijvanich P, Voravud N, et al (2001). Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol, 36, 830-6. https://doi.org/10.1007/s005350170005
  7. Chow V, Yuen AP, Lam KY, et al (2001). Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck, 23, 286-91. https://doi.org/10.1002/hed.1032
  8. Diccianni MB, Yu J, Hsiao M, et al (1994). Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood, 84, 3105-12.
  9. Hsiao MH, Yu AL, Yeargin J, et al (1994). Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood, 83, 922-30.
  10. Konikova E, Kusenda J, Babusikova O (1999). Flow cytometry of p53 protein expression in some hematological malignancies. Neoplasma, 46, 368-76.
  11. Morita T, Tachikawa N, Kumamaru T, et al (2000). Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients. Eur Urol, 37, 79-84. https://doi.org/10.1159/000020104
  12. Park JS, Park TH, Lim YT, et al (2000). Clinical significance of p53 protein overexpression and serum anti-p53 antibodies in patients with acute and chronic leukemia. Korean J Clin Pathol, 20, 247-54.
  13. Prokocimer M, Peller S (2012). Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: first report. Med Oncol, 29, 1148-50. https://doi.org/10.1007/s12032-011-9916-x
  14. Rajkumar T (2001). Growth factors and growth factor receptors in cancer. Curr Sci, 81, 535-41.
  15. Sahu G, Jena RK (2011). Clinical significance of P53 and Bcl-2 in acute myeloid leukemia patients of Eastern India. Hematol Rep, 3, 91-4.
  16. Schlessinger J, Ullrich A (1992). Growth-factor signaling by receptor tyrosine kinase. Neuron, 9, 383-91. https://doi.org/10.1016/0896-6273(92)90177-F
  17. Segawa Y, Takigawa N, Mandai K, et al (1997). Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation. Lung Cancer, 16, 229-38. https://doi.org/10.1016/S0169-5002(97)82785-7
  18. Shim KS, Kim KH, Park BW, et al (1998). Increased serum levels of mutant p53 proteins in patients with colorectal cancer. J Korean Med Sci, 13, 44-8. https://doi.org/10.3346/jkms.1998.13.1.44
  19. Sobti RC, Parashar K (1998). A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat Res, 422, 271-7. https://doi.org/10.1016/S0027-5107(98)00207-3
  20. Sun JZ, Lu Y, Xu Y, et al (2012). Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis. Hematol Oncol, 30, 89-97. https://doi.org/10.1002/hon.1002
  21. Suwa H, Ohshio G, Okada N, et al (1997). Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut, 40, 647-53. https://doi.org/10.1136/gut.40.5.647
  22. Wattel E, Preudhomme C, Hecquet B, et al (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148-57.
  23. Xiaoming S, Weiping W (2009). Academy of pediatrics, 7th ed. People's medical publishing house. 375.
  24. Yamazaki H, Kijima H, Ohnishi Y, et al (1998). Inhibition of tumor growth by ribozyme mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst, 90, 581-7. https://doi.org/10.1093/jnci/90.8.581
  25. Zhu YM, Foroni L, McQuaker IG, et al (1999). Mechanisms of relapse in acute leukaemia, Involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukemia. Bri J Cancer, 79, 1151-7. https://doi.org/10.1038/sj.bjc.6690183

Cited by

  1. Allogeneic Hemopietic Stem Cell Transplants for the Treatment of B Cell Acute Lymphocytic Leukemia vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6127